New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
14:44 EDTSCMPSucampo issues statement regarding AADPA meeting's vote
Sucampo Pharmaceuticals issued the following statement regarding the Anesthetic and Analgesic Drug Products Advisory Committee meeting's vote: "As a chloride channel activator, AMITIZA has a different mechanism of action than the peripherally acting mu-opioid receptor antagonists and is approved by the U.S.FDA to treat opioid induced constipation. AMITIZA has been prescribed over eight million times over more than eight years and has a well-tolerated safety profile, with no cardiovascular precautions or warnings. FDA did not require Sucampo to reevaluate our clinical data for cardiovascular risks, as they did for the PAMORAS, and AMITIZA was therefore not a participant in this week's Advisory Committee," said Peter Greenleaf, CEO of Sucampo. "We believe the outcome of today's Advisory Committee further demonstrates the FDA's awareness that safety, specifically the potential cardiovascular safety associated with the PAMORAS class of compounds, is paramount in assessing alternative therapies for OIC, which is a severe condition that affects 40-80 percent of the estimated 250 million patients who receive prescriptions for opioids each year for non-cancer pain. OIC is still widely under-identified and under-managed, and we believe that potential new entrants to the market can help increase overall awareness of the condition. We remain committed to maximizing AMITIZA's potential and to bringing it to physicians and patients worldwide for the treatment of OIC."
News For SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
09:12 EDTSCMPSucampo price target raised to $36 from $31 at H.C. Wainwright
H.C. Wainwright said Sucampo's proposed acquisition of its supplier R-Tech Ueno is about "a lot more" than just lower costs and direct control over the supply chain, noting that Sucampo will also acquire several early pipeline assets via the deal. The firm, which contends that the market has "yet to fully comprehend the impact of this acquisition," raised its price target on Sucampo shares to $36 from $31.
August 26, 2015
07:47 EDTSCMPSucampo to host conference call
Subscribe for More Information
06:19 EDTSCMPSucampo launches tender offer to acquire R-Tech Ueno for $278M
Sucampo Pharmaceuticals announced the launch of an all-cash tender offer in Japan by Sucampo's Japanese subsidiary and the execution of a separate share purchase agreement with certain shareholders of R-Tech Ueno to acquire all outstanding shares of R-Tech Ueno for a total consideration of JPY33 billion, or approximately $278M, inclusive of approximately $54M in cash and 2.5M Sucampo shares, held by R-Tech Ueno. The purchase price reflects a 16% premium over R-Tech Ueno's one-month volume weighted average price and a 16% premium over R-Tech Ueno's three-month volume weighted average price. Assuming a successful completion of the acquisition, for full year 2016, excluding amortization and debt costs related to the proposed transaction, Sucampo expects to achieve net income of $55M to $60M , earnings per share of $1.20 to $1.30, and adjusted EBITDA of $95M to $100M. In addition, Sucampo expects to achieve pre-tax operational synergies of approximately $5M on an annualized basis in 2016. Sucampo does not expect the acquisition to have a material impact on 2015 results given the expected timing of transaction close. R-Tech Ueno is a Japanese pharmaceutical company that manufactures AMITIZA for Sucampo and Sucampo's commercialization partners, Takeda Pharmaceuticals, Mylan N.V. and Harbin Gloria Pharmaceuticals. R-Tech Ueno also receives revenue from sales of RESCULA in Japan. In addition, the company has a diverse pipeline of drug candidates in various stages of development in gastroenterology, ophthalmology, autoimmune and inflammatory diseases, and oncology. In the tender offer, which has been unanimously approved by the Board of Directors of both companies, Sucampo's Japanese subsidiary Sucampo Pharma, LLC will offer JPY1,900 per share in cash for the shares of R-Tech Ueno. Sucampo is expecting to acquire 56% of the outstanding shares of R-Tech Ueno in the tender offer. Separately, Sucampo has entered into agreement with R-Tech Ueno's founders and a related entity to acquire the remaining 44% of R-Tech Ueno shares for JPY1,400 per share; the closing of this share purchase is conditioned on the closing of the tender offer. The tender offer period is expected to end on October 13, 2015, assuming the tender offer achieves the minimum acceptance threshold, regulatory approvals and other customary conditions, subject to our right to extend the offer. Following completion of the tender offer and the closing of the share purchase agreement with the founders, Sucampo will acquire all remaining outstanding shares of R-Tech Ueno not acquired through the tender offer through a squeeze-out process. The squeeze out process may take up to 13 weeks to complete. The aggregate acquisition price of R-Tech Ueno will be approximately $278 million. Sucampo expects to close the acquisition in the fourth quarter of 2015.
August 24, 2015
09:45 EDTSCMPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:29 EDTSCMPSucampo initiated with a Buy at H.C. Wainwright
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use